Press Releases
November 8th 2011
Karyopharm Therapeutics Announces Presentations by Seven Collaborators showing
Major Progress in advancing Selective Inhibitors of Nuclear Export (SINE) for Hematologic
Malignancies at American Society of Hematology (ASH) Meeting.
Read more >
November 2nd 2011
Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand
Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export
(SINE) for Cancer.
Read more >
October 11th 2011
Karyopharm and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
Read more >
January 6th 2011
Multiple Myeloma Research Foundation (MMRF)
Invests $3 Million in Development of Next-Generation Treatments.
Read more >
January 5th 2011
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer.
Read more >
November 3th 2010
Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders.
Read more >
June 7th 2010
Karyopharm Therapeutics has signed an agreement with O2h, a discovery services company,
in order to further its lead small molecule program toward the nomination of a development candidate.
Read more >
April 30th 2009
The crystal structure of CRM1 in complex with a substrate called snurportin 1 was solved by our collaborator
Prof. Yuh Min Chook (University of Texas Southwestern).